SLC6A12 and epilepsy: Inhibitors of GAT-2, GAT-3, and BGT-1 are currently considered as potential drug targets for treatment of epilepsy [23] as they counterbalance the decreased calcium-independent GABA release, which is one of the main features in TLE hippocampus [48].